Ror2, a developmentally regulated kinase, is associated with tumor growth, apoptosis, migration, and invasion in renal cell carcinoma

Oncology Research

Volumn 25, Issue 2, 2017, Pages 195-205

  Yang, Chun Ming ^a   Ji, Shan ^b   Li, Yan ^a   Fu, Li Ye ^a   Jiang, Tao ^a   Meng, Fan Dong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The Fifth People's Hospital of Shenyang   (China)

Author keywords

Apoptosis; Invasion; Migration; Receptor tyrosine kinase like orphan receptor 2 (Ror2); Renal cell carcinoma (RCC)

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLINE; GELATINASE A; MATRIGEL; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 2; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; ROR2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RENAL CANCER CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR PROMOTION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL MOTION; DRUG SCREENING; ENZYMOLOGY; GENETICS; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013641742     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14732772150424     Document Type: Article

References (31)

1. Koul, H.; Huh, J. S.; Rove, K. O.; Crompto, L.; Koul, S.; Meacham, R. B.; Kim, F. J. Molecular aspects of renal cell carcinoma: A review. Am. J. Cancer Res. 1:240-254; 2011.
2. Cowey, C. L.; Rathmell, W. K. Using molecular biology to develop drugs for renal cell carcinoma. Expert Drug Dis. 3:311-327; 2008.
3. Garg, M.; Kanojia, D.; Khosla, A.; Dudha, N.; Sati, S.; Chaurasiya, D.; Jagadish, N.; Seth, A.; Kumar, R.; Gupta, S.; Gupta, A.; Lohiya, N. K.; Suri, A. Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res. 68:8240-8248; 2008.
4. Katagiri, T.; Togashi, A.; Ashida, S.; Fujioka, T.; Maruyama, O.; Wakumoto, Y.; Sakamoto, Y.; Fujime, M.; Kawachi, Y.; Shuin, T.; Nakamura, Y. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma (RCC) and potential target for molecular therapy. Cancer Res. 66:304-304; 2006.
5. Yoda, A.; Oishi, I.; Minami, Y. Expression and function of the Ror-family receptor tyrosine kinases during development: Lessons from genetic analyses of nematodes, mice, and humans. J. Recept. Signal Transduct. Res. 23:1-15; 2003.
6. Schwabe, G. C.; Trepczik, B.; Süring, K.; Brieske, N.; Tucker, A. S.; Sharpe, P. T.; Minami, Y.; Mundlos, S. Ror2 knockout mouse as a model for the developmental pathology of autosomal recessive Robinow syndrome. Dev. Dyn. 229:400-410; 2004.
7. Debebe, Z.; Rathmell, W. K. Ror2 as a therapeutic target in cancer. Pharmacol. Ther. 150:143-148; 2015.
8. Morioka, K.; Tanikawa, C.; Ochi, K.; Daigo, Y.; Katagiri, T.; Kawano, H.; Kawaguchi, H.; Myoui, A.; Yoshikawa, H.; Naka, N.; Araki, N.; Kudawara, I.; Ieguchi, M.; Nakamura, K.; Nakamura, Y.; Matsuda, K. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 100:1227-1233; 2009.
9. Wright, T. M.; Brannon, A. R.; Gordan, J. D.; Mikels, A. J.; Mitchell, C.; Chen, S.; Espinosa, I.; van de Rijn, M.; Pruthi, R.; Wallen, E.; Edwards, L.; Nusse, R.; Rathmell, W. K. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 28:2513-2523; 2009.
10. O'Connell, M. P.; Fiori, J. L.; Xu, M.; Carter, A. D.; Frank, B. P.; Camilli, T. C.; French, A. D.; Dissanayake, S. K.; Indig, F. E.; Bernier, M.; Taub, D. D.; Hewitt, S. M.; Weeraratna, A. T. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29:34-44; 2010.
11. Lara, E.; Calvanese, V.; Huidobro, C.; Fernández, A. F.; Moncada-Pazos, A.; Obaya, A. J.; Aguilera, O.; González-Sancho, J. M.; Sánchez, L.; Astudillo, A.; Muñoz, A.; López-Otín, C.; Esteller, M.; Fraga, M. F. Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol. Cancer 9:170; 2010.
12. Kobayashi, M.; Shibuya, Y.; Takeuchi, J.; Murata, M.; Suzuki, H.; Yokoo, S.; Umeda, M.; Minami, Y.; Komori, T. Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 107:398-406; 2009.
13. Henry, C.; Quadir, A.; Hawkins, N. J.; Jary, E.; Llamosas, E.; Kumar, D.; Daniels, B.; Ward, R. L.; Ford, C. E. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. J. Cancer Res. Clin. Oncol. 141:243-254; 2015.
14. Zhang, H. J.; Tao, J.; Sheng, L.; Hu, X.; Rong, R. M.; Xu, M.; Zhu, T. Y. Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. OncoTargets Ther. 9:1801-1812; 2016.
15. Mondal, J.; Bishayee, K.; Panigrahi, A. K.; Khuda-Bukhsh, A. R. Low doses of ethanolic extract of Boldo (Peumus boldus) can ameliorate toxicity generated by cisplatin in normal liver cells of mice in vivo and in WRL-68 cells in vitro, but not in cancer cells in vivo or in vitro. J. Integr. Med. 12:425-438; 2014.
16. Zhang, X. F.; Zhu, J.; Geng, W. Y.; Zhao, S. J.; Jiang, C. W.; Cai, S. R.; Cheng, M.; Zhou, CY.; Liu, Z. B. Electroacupuncture at Feishu (BL13) and Zusanli (ST36) down-regulates the expression of orexins and their receptors in rats with chronic obstructive pulmonary disease. J. Integr. Med. 12:417-424; 2014.
17. Wang, S.; Chong, Z. Z.; Shang, Y. C.; Maiese, K. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr. Neurovasc. Res. 9:91-101; 2012.
18. Stommel, J. M.; Kimmelman, A. C.; Ying, H.; Nabioullin, R.; Ponugoti, A. H.; Wiedemeyer, R.; Stegh, A. H.; Bradner, J. E.; Ligon, K. L.; Brennan, C.; Chin, L.; DePinho, R. A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290; 2007.
19. Zhang, C.; Hu, Y.; Wan, J.; He, H. MicroRNA-124 suppresses the migration and invasion of osteosarcoma cells via targeting ROR2-mediated non-canonical Wnt signaling. Oncol. Rep. 34:2195-2201; 2015.
20. Lu, C.; Wang, X.; Zhu, H.; Feng, J.; Ni, S.; Huang, J.; Overexpression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer. Oncotarget 6:24912; 2015.
21. Lai, S. S.; Xue, B.; Yang, Y.; Zhao, L.; Chu, C. S.; Hao, J. Y.; Wen, C. J. Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE. Cancer Genet. 205:552-562; 2012.
22. Rasmussen, N. R.; Debebe, Z.; Wright, T. M.; Brooks, S. A.; Sendor, A. B.; Brannon, A. R.; Hakimi, A. A.; Hsieh, J. J.; Choueiri, T. K.; Tamboli, P.; Maranchie, J. K.; Hinds, P.; Wallen, E. M; Simpson, C.; Norris, J. L.; Janzen, W. P. Rathmell WK11 Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. PLoS One 9:e116101; 2014.
23. Henry, C.; Llamosas, E.; Djordjevic, A.; Hacker, N.; Ford, C. Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis 5:e226; 2016.
24. Strzalka, W.; Ziemienowicz, A. Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation. Ann. Bot. 107:1127-1140; 2011.
25. Stoimenov, I.; Helleday, T. PCNA on the crossroad of cancer. Biochem. Soc. Trans. 37:605-613;2009.
26. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer 9:153-166; 2009.
27. Ohba, K.; Miyata, Y.; Matsuo, T.; Asai, A.; Mitsunari, K.; Shida, Y.; Kanda, S.; Sakai, H. High expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma. Int. J. Clin. Exp. Pathol. 7:3158-3165; 2014.
28. Kurban, G.; Hudon, V.; Duplan, E.; Ohh, M.; Pause, A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 66:1313-1319; 2006.
29. Billiard, J.; Way, D. S.; Seestaller-Wehr, L. M.; Moran, R. A.; Mangine, A.; Bodine, P. V. The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol. Endocrinol. 19:90-101; 2005.
30. Topol, L.; Jiang, X.; Choi, H.; Garrett-Beal, L.; Carolan, P. J.; Yang, Y. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J. Cell Biol. 162:899-908;2003.
31. Li, C.; Chen, H.; Hu, L.; Xing, Y.; Sasaki, T.; Villosis, M. F.; Li, J.; Nishita, M.; Minami, Y.; Minoo, P. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol. Biol. 9:11; 2008.